NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells $2,319,850.00 in Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 65,000 shares of the firm’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $35.69, for a total transaction of $2,319,850.00. Following the sale, the chief accounting officer owned 24,353 shares in the company, valued at $869,158.57. The trade was a 72.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

NewAmsterdam Pharma Stock Performance

Shares of NAMS stock opened at $33.68 on Friday. NewAmsterdam Pharma Company N.V. has a 52-week low of $16.95 and a 52-week high of $42.21. The firm has a market capitalization of $3.94 billion, a PE ratio of -18.82 and a beta of 0.02. The stock has a fifty day simple moving average of $33.34 and a two-hundred day simple moving average of $34.20.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings data on Tuesday, March 31st. The company reported ($0.40) EPS for the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. The business had revenue of $3.04 million during the quarter. On average, sell-side analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.76 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of NAMS. Farther Finance Advisors LLC grew its holdings in shares of NewAmsterdam Pharma by 4,425.0% in the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock valued at $25,000 after purchasing an additional 708 shares in the last quarter. Wells Fargo & Company MN raised its stake in NewAmsterdam Pharma by 50.0% during the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after purchasing an additional 300 shares in the last quarter. KBC Group NV bought a new position in NewAmsterdam Pharma during the first quarter valued at $37,000. Navalign LLC bought a new position in NewAmsterdam Pharma during the fourth quarter valued at $46,000. Finally, AdvisorNet Financial Inc purchased a new position in shares of NewAmsterdam Pharma in the 1st quarter worth $82,000. 89.89% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on NAMS. Truist Financial assumed coverage on shares of NewAmsterdam Pharma in a report on Wednesday, March 18th. They set a “buy” rating and a $57.00 price objective for the company. HC Wainwright raised shares of NewAmsterdam Pharma to a “strong-buy” rating in a report on Thursday, February 19th. Needham & Company LLC upped their target price on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Tuesday, April 21st. Finally, Guggenheim boosted their price target on shares of NewAmsterdam Pharma from $41.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, February 19th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $48.00.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.